VP025, a novel drug formulation based on phospholipid microparticles incorporating phosphatidylglycerol, can inhibit neuroinflammation. VP025 may inhibit immune system activation and protect motoneurons from injury. It also shows the ability... It also shows the ability to reduce inflammation across the blood-brain barrier and improve correlates of memory and learning function.
- Mechanism
- Curator reviewed
VP025 is being developed to exert its anti-inflammatory effects using an cell clearance mechanism. VP025, a preparation of phospholipid microparticles containing phosphatidylglycerol, has been shown to exert anti-inflammatory effects in the brain, abrogating age-induced up-regulation of IL-1 beta and IL-1 beta -induced signalling, and reducing the activation of c-Jun N-terminal kinase (JNK), a kinase involved in the inflammatory process.
- Primary indication
- Investigated for use/treatment in alzheimer's disease and inflammatory disorders (unspecified).Curator reviewed
- Code names
- VP025
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with VP025, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account